Dopaminergic Therapy for Frontotemporal Dementia Patients

Dementia Clinical Trial

Official title:

Dopaminergic Therapy for Frontotemporal Dementia Patients: an Interventional, Multi-site, Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of RTG Treatment in Patients With Behavioral FTD

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04937452
• Other study ID #: EudraCT 2019-002997-30
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: June 3, 2021
• Est. completion date: April 1, 2024

Study information

• Verified date: July 2022
• Source: I.R.C.C.S. Fondazione Santa Lucia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase IIa 24-week randomized, double-blind, placebo-controlled study. The study is designed to evaluate the efficacy and safety of Rotigotine (RTG) transdermal administration at the dosage of 4 mg or 6 mg per day versus Placebo (PLC) in newly diagnosed behavioural Frontotemporal Dementia (bvFTD) patients. 75 patients with a diagnosis of probable bvFTD will be randomly allocated to the 3 treatment arms (RTG 4mg/day, RTG 6mg/day or PLC), with 25 patients per group. Clinical and neurophysiological measurements and brain metabolism via FDG-PET will be collected before and after drug administration.

Description:

The current study has the ambition to provide the first-time evidence of the clinical impact, at cognitive and behavioral level, of a dopamine-based treatment in newly diagnosed bvFTD patients.

To evaluate the cognitive and behavioral effects of RTG administration, the investigators will employ a battery of tests assessing global cognition, executive functions, language and behavior.

The battery will include: Neuropsychiatric Inventory (NPI) and Frontal Behavioral Inventory (FBI) to evaluate behavior, Clinical Dementia Rating Scale-Frontotemporal Dementia Sum Of Boxes (CDR-FTD SOB) to evaluate global disease severity, Frontal Assessment Battery (FAB) to evaluate frontal functions, Screening for aphasia in Neurodegeneration (SAND) to evaluate language functions, Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) to evaluate activities of daily living, the Addenbrooke's Cognitive Examination Revised (ACE-R) to evaluate global cognition.

To evaluate changes in brain metabolism the investigators will perform 2 FDG-PET scans before starting the treatment and at the end of week 24.

Neurophysiological investigations will be performed to identify quantifiable biomarkers underlying the effects induced by dopamine agonist on the bvFTD brain. In particular, the investigators will use multimodal neurophysiological tools based on TMS-EMG and TMS-EEG. More specifically, different paired-pulse TMS protocols will be used to evaluate in vivo the activity of different intracortical circuits, such as short intracortical inhibition (SICI), reflecting GABA(A)-ergic neurotransmission; long intracortical inhibition (LICI), evaluating GABA(B)-ergic neurotransmission; short afferent inhibition (SAI) evaluating cholinergic neurotransmission and intermittent theta burst stimulation (iTBS) probing cortical plasticity mechanisms, such as long- term potentiation (LTP). The effects of these protocols will be evaluated by means of motor-evoked potentials, recordable with EMG. TMS-EEG will be used to measure the effects of RTG on frontal and parieto-temporal cortical activity, in terms of cortical excitability, oscillatory activity and connectivity. The investigators will evaluate the effects of the DA drug on brain activity and plasticity by analyzing MEPs and TEPs before and after the treatment. The investigators expect to find modulations in the high EEG frequencies (beta and gamma oscillatory activities) and/or in the indexes of cortical reactivity and plasticity (amplitude of TEPs and MEPs) that correlate with improvement in clinical assessment.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 75
• Est. completion date: April 1, 2024
• Est. primary completion date: December 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

1. The patient has a diagnosis of probable Frontotemporal dementia behavioural variant (bv-FTD) based on the International consensus clinical diagnostic criteria described by Rascovsky et al., 2011.

2. The patient is a man or a woman, aged from 40 to 80 years.

3. The patient has a Clinical Dementia Rating-FTD (CDR-FTD) total score of =2 at Screening.

4. The patient has not been treated with acetylcholinesterase inhibitor (AChEI), i.e., donepezil, galantamine, or rivastigmine, at the time of screening.

5. The patient is able to comply with the study procedures in the view of the investigator.

6. Evidence of frontotemporal hypometabolism at PET imaging.

7. Evidence of amyloid markers excluding Alzheimer's disease (cerebrospinal fluid Abeta/Tau dosages or amyloid PET imaging).

8. Signature and date of written ICF prior to entering in the study

9. Female patient must be neither pregnant nor breastfeeding. Women of childbearing potential should be willing to use contraception while receiving Rotigotine and for six months after its last assumption

Exclusion Criteria:

1. Significant neurodegenerative disorder of the central nervous system other than FTD e.g., Alzheimer's disease, Lewy body dementia, Parkinson's disease, multiple sclerosis, progressive supranuclear palsy, normal pressure hydrocephalus, Huntington's disease, any condition directly or indirectly caused by Transmissible Spongiform Encephalopathy (TSE), Creutzfeldt-Jakob Disease (CJD), variant Creutzfeldt-Jakob Disease (vCJD), or new variant Creutzfeldt-Jakob Disease (nvCJD)

2. Significant intracranial focal or vascular pathology seen on brain MRI scan within a maximum of 6 months before Baseline leading to a diagnosis other than probable FTD.

3. The patients has history of seizure (with the exception of febrile seizures in childhood).

4. Metal implants in the head (except dental), pacemaker, cochlear implants, or any other non-removable items that are contraindications to MR imaging.

5. Treatment currently or within 3 months before Baseline with any of the following medications: Typical and Atypical antipsychotics (i.e., Clozapine, Olanzapine); Antiepileptics drugs (i.e., Carbamazepine, Primidone, Pregabalin, Gabapentin); Antidepressants (i.e., Citalopram, Duolxetine, Paroxetine).

Related Conditions & MeSH terms

• Alzheimer Disease
• Aphasia
• Aphasia, Primary Progressive
• Brain Diseases
• Central Nervous System Diseases
• Communication Disorders
• Dementia
• Disease
• Frontotemporal Dementia
• Frontotemporal Lobar Degeneration
• Language Disorders
• Mental Disorders
• Metabolic Disease
• Metabolic Diseases
• Nervous System Diseases
• Neurobehavioral Manifestations
• Neurocognitive Disorders
• Neurodegenerative Diseases
• Neurologic Manifestations
• Pick Disease of the Brain
• Speech Disorders
• TDP-43 Proteinopathies

Intervention

Drug:
• Rotigotine 4Mg/24Hrs Patch
Rotigotine 4 mg/24Hrs administration for 24 weeks
• Rotigotine 6Mg/24Hrs Patch
Rotigotine 6 mg/24Hrs administration for 24 weeks
• Placebo
Placebo administration for 24 weeks

Locations

Country	Name	City	State
Italy	Department of Neurology, University of Brescia	Brescia
Italy	Giacomo Koch	Rome
Italy	Santa Lucia Foundation	Rome

Sponsors (2)

Lead Sponsor	Collaborator
I.R.C.C.S. Fondazione Santa Lucia	Alzheimer's Drug Discovery Foundation

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frontal Assessment Battery (FAB)	Battery to evaluate executive functions. The scores range from 0-18 with a higher score meaning less cognitive impairment.	24 weeks
Secondary	Neuropsychiatric Inventory (NPI) scale	Battery to assess behavioral changes. The scores range from 0-144 with a higher score meaning more severe behavioural disturbances.	24 weeks
Secondary	Frontal Behavioural Inventory (FBI)	Battery to assess behavioral changes. The scores range from 0-72 with a higher score meaning more severe behavioural disturbances.	24 weeks
Secondary	Clinical Dementia Rating scale-Frontotemporal dementia Sum Of Boxes (CDR-FTDSOB)	Battery to evaluate global disease severity. The scores range from 0-24 with a higher score meaning higher disease severity.	24 weeks
Secondary	Screening for aphasia in Neurodegeneration (SAND) scale	Battery to evaluate language functions. The scores range from 0-84 with a higher score meaning less severe language deficits.	24 weeks
Secondary	Mini Mental State Examination (MMSE)	battery to evaluate global cognition. The scores range from 0-30 with a higher score meaning less cognitive impairment.	24 weeks
Secondary	Addenbrooke's Cognitive Examination Revised (ACE-R)	battery to evaluate global cognition. The scores range from 0-100 with a higher score meaning less cognitive impairment.	24 weeks
Secondary	Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)	battery to evaluate activities of daily living. The scores range from 0-78 with lower scores indicating more severe functional impairment.	24 weeks
Secondary	CGIC questionnaire	questionnaire to evaluate clinically meaningful change	24 weeks
Secondary	18F-FDG CT/PET	Change in brain glucose metabolism will be measured via FDG-PET	24 weeks
Secondary	Long intracortical inhibition (LICI)	TMS protocol to evaluate GABA(B)ergic transmission	24 weeks
Secondary	Short intracortical inhibition (SICI)	TMS protocol to evaluate GABA(B)ergic transmission	24 weeks
Secondary	Short-Latency Afferent Inhibition (SAI)	TMS protocol to evaluate cholinergic transmission	24 weeks
Secondary	Intermittent Theta Burst Stimulation (iTBS)	TMS protocol to evaluate cortical plasticity	24 weeks
Secondary	TMS-EEG	power in beta-gamma band to evaluate prefrontal cortical oscillatory activity	24 weeks
Secondary	Nature, frequency and severity of adverse events (AEs)	To assess the safety and tolerability	24 weeks